Slide background

Novel Approaches to the Treatment of Neurological Diseases

Slide background

Curemark Featured in Fast Company with Google & Purina (Nestle):
Great Companies Solve Problems That Matter

Consider Curemark, a biotech company founded by pediatric doctor Joan Fallon. She noticed many autistic children were low on a
certain kind of enzyme for processing protein.

Read More
Slide background

Curemark Begins NDA Submission
for CM-AT Autism Treatment

Curemark LLC announced that it has begun the rolling submission of a New Drug Application (NDA) for CM-AT, the company's
autism treatment, with the U.S. Food and Drug Administration.

Read More
Slide background

Curemark Secures $18.5 Million Financing

Curemark LLC announced today the closing of $18.5 million in common equity financing led by a leading European institutional investor.
Curemark will use the funds for the completion and filing requirements for its New Drug Application (NDA) for CM-AT, the company's autism
treatment, and the development of the other therapies in its pipeline.
Read More

All About The Kids

At Curemark, our goal is to develop first-in-class compounds with the intent of improving the lives of children living with Autism and others living with severe neurologic diseases.

Watch this video to learn more.


Curemark has a Late-Stage Autism program and lead candidates for ADHD, Schizophrenia, Parkinson’s and Addiction.


Our technology focuses on addressing exocrine pancreatic deficiencies to potentially improve symptoms of several neurologic diseases.


To see the most up-to-date press and media coverage on Curemark please visit our news section. For inquiries contact

Latest News

Get in Touch

LinkedIn copy Twitter copy Facebook copy